Natto / Vitamin K2 (for Arteries) — Research Profile

If you take warfarin or another vitamin K antagonist, do NOT take supplemental K2 without your doctor's explicit guidance. Vitamin K2 activates clotting factors that warfarin is designed to inhibit. However, some practitioners do use stable, low-dose K2 alongside warfarin with careful INR monitoring. If you take DOACs (like rivaroxaban or apixaban), K2 is generally safe since these drugs do not work through vitamin K pathways. Always consult your prescriber.

Both are forms of vitamin K2 but differ significantly. MK-7 (from natto) has a long half-life (~72 hours), allowing once-daily dosing and sustained blood levels. MK-4 has a very short half-life (~6 hours) and requires dosing 3 times daily. For arterial health, MK-7 is preferred because it maintains consistent activation of matrix Gla protein (the anti-calcification enzyme) ^[1]. A 3-year RCT confirmed that 180mcg MK-7 daily significantly reduced arterial stiffness in postmenopausal women, with large-cohort data linking higher menaquinone intake to lower coronary heart disease mortality ^[2]. MK-4 is primarily studied for bone health at high doses (45mg/day) in Japan.

No, they are completely different compounds that both happen to come from natto (fermented soybeans). Nattokinase is a fibrinolytic enzyme that helps break down fibrin in blood clots, supporting healthy blood flow. Vitamin K2 (MK-7) is a fat-soluble vitamin that activates proteins preventing arterial calcification. Many natto-derived supplements contain both, but they should be evaluated separately. Some nattokinase products are specifically processed to remove vitamin K2, making them safer for warfarin users.

For arterial outcomes, MK-7 is the best-evidenced menaquinone form: it was the specific form that improved arterial stiffness at 180 mcg/day over three years, and it is well absorbed with a longer half-life than vitamin K1 (phylloquinone). MK-4 is produced by the body from phylloquinone but has not shown the same arterial-stiffness data at supplement doses. Whole natto delivers both MK-7 (about 850 mcg per 3-ounce serving) and nattokinase, though no head-to-head trial establishes one commercial form as superior to another.

The strongest controlled evidence is for MK-7: 180 mcg/day for three years significantly reduced arterial stiffness (carotid-femoral pulse wave velocity and Stiffness Index) in healthy postmenopausal women. Observationally, higher dietary menaquinone (K2) intake was associated with lower coronary heart disease risk in the Rotterdam cohort, though observational data cannot prove causation. Nattokinase has been shown to acutely enhance fibrinolysis and anticoagulation markers, but its effect on hard cardiovascular outcomes such as heart attack or stroke has not been established.

There is no single established dose because the category covers two substances. The arterial-stiffness trial used MK-7 at 180 mcg/day, while nattokinase studies of clot-related effects have used around 2,000 FU. Note that the general vitamin K Adequate Intake (120 mcg/day for men, 90 mcg/day for women) reflects overall adequacy and is not a target for arterial benefit. No dose has been validated for reducing cardiovascular events.

Because vitamin K2 is fat-soluble, taking it with a meal containing some fat improves its absorption, but no study has compared morning versus evening dosing for arterial outcomes. The MK-7 arterial-stiffness trial simply used a fixed daily dose without specifying time of day. For nattokinase, no optimal time has been directly tested; if it is used alongside anticoagulant medication, spacing and timing should be coordinated with a clinician rather than self-selected.

Vitamin K2 itself has few side effects and low toxicity, which is why no Tolerable Upper Intake Level was set. The nattokinase component drives the main safety consideration: by prolonging clotting time and raising fibrinolytic markers, it can increase the tendency to bruise or bleed, particularly in people already prone to bleeding. Mild digestive upset is also possible with natto-derived products.

Yes, and this is the most important safety point. Vitamin K, including K2, directly opposes warfarin: people on warfarin or similar anticoagulants must keep vitamin K intake consistent because sudden changes can increase or decrease the drug's effect. Separately, the nattokinase component enhances fibrinolysis and prolongs clotting time, so combining it with anticoagulants (warfarin, DOACs, heparin) or antiplatelet drugs like aspirin or clopidogrel could add to bleeding risk. Anyone on these medications should involve their prescriber before use.

The best-supported candidates are people focused on arterial stiffness or vascular aging, such as postmenopausal women, since MK-7 at 180 mcg/day improved arterial stiffness in that group and higher dietary K2 intake tracked with lower coronary heart disease risk in cohort data. It is not appropriate for people taking warfarin, since vitamin K antagonizes the drug, nor for those on other anticoagulant or antiplatelet therapy without medical oversight, given the nattokinase bleeding risk. Those with bleeding disorders or upcoming surgery should also avoid the enzyme component.

The two components in this category work on very different timelines. Nattokinase acts acutely: a single 2,000 FU dose raised fibrinolytic markers (D-dimer up ~44%) and prolonged clotting time within 2-8 hours in healthy young men. Vitamin K2 as MK-7, by contrast, targets arterial stiffness slowly; the trial showing benefit gave 180 mcg daily and only reached statistical significance for carotid-femoral pulse wave velocity after three years in postmenopausal women.

Vitamin K2 has a strong long-term safety profile: the Food and Nutrition Board set no Tolerable Upper Intake Level for vitamin K because of its low toxicity, and MK-7 at 180 mcg/day was taken for three years in a controlled trial without safety concerns. Nattokinase is different: because it enhances clot breakdown, controlled long-term safety data are limited, and ongoing use carries a theoretical bleeding risk that has not been characterized over multi-year periods. Anyone on anticoagulants should not use either component long-term without medical supervision.

For vitamin K2 there is no established Tolerable Upper Intake Level; the FNB declined to set one because of vitamin K's low potential for toxicity. Nattokinase is the component to watch on the high end: a single 2,000 FU dose measurably prolonged activated partial thromboplastin time and lowered factor VIII activity, so larger or stacked doses could plausibly push clotting times far enough to raise bleeding risk. Excess is therefore defined more by bleeding-related effects of the enzyme than by any toxic ceiling for the vitamin.

Vitamin K2 is fat-soluble and is commonly paired with vitamin D and taken alongside dietary fat to aid absorption, with no known adverse nutrient interaction. The main caution is the nattokinase fraction: because it prolongs clotting time and boosts fibrinolysis, stacking it with other blood-thinning supplements such as fish oil, garlic, ginkgo, or high-dose vitamin E could compound bleeding risk. Combining is otherwise reasonable, but the fibrinolytic component makes additive anticoagulant effects the real limiting factor.

These are two standardizations, so check which you are buying. Nattokinase potency is expressed in fibrinolytic units (FU); trials of its clot-related effects used 2,000 FU. Vitamin K2 is standardized by menaquinone form and microgram dose, most often MK-7 (the form and 180 mcg dose used in the arterial-stiffness trial) rather than the shorter-acting MK-4. If you want the enzyme only, note that some natto-derived products still contain vitamin K2, which matters for anyone on warfarin.